REGENXBIO Inc. RGNX

Updated: 9 Aug 2026

NASDAQ | Biotech | Gene therapy / biotechnology

No signal published yet

We already track REGENXBIO and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow REGENXBIO free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Gene therapy / biotechnology
We're already tracking REGENXBIO Inc. — here are the latest events we've registered

Recent News

  • On August 6, 2026, REGENXBIO reported second-quarter 2026 financial results featuring $108.0 million in revenue and $22.7 million in net income. Results were supported by a $100 million milestone payment from AbbVie tied to patient dosing in a Phase IIb/III diabetic retinopathy trial. The company noted that recent capital raises boosted its pro forma cash balance above $310 million.

What Firelda Watch includes for REGENXBIO Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of REGENXBIO Inc. will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Hansa Biopharma AB (publ)
HNSA
HOLD
Bioarctic
BIOA B
BUY
Sprint Bioscience AB (publ)
SPRINT
NEUTRAL
Xbrane Biopharma AB (publ)
XBRANE
HOLD
SynAct Pharma AB
SYNACT
HOLD

Biotech

More companies in this sector

Want to follow REGENXBIO Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow REGENXBIO free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

REGENXBIO Inc. RGNX
REGENXBIO — follow and we'll monitor it
Follow REGENXBIO free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.